Current Opinion in Hematology volume 17, issue 2, P125-132 2010 DOI: 10.1097/moh.0b013e3283366c59 View full text
|
|
Share
Animesh Pardanani, Ayalew Tefferi

Abstract: Primary data from a large series of patients have enabled delineation of well defined prognostic groups in systemic mastocytosis and clarification of the merits of conventional drugs for aggressive systemic mastocytosis.